IRVINE, Calif., July 11, 2019 /PRNewswire/ -- Cryoport, Inc.
(NASDAQ: CYRX) (NASDAQ: CYRXW) and EVERSANA™ have announced a
strategic alliance to further create a fully integrated
regenerative medicine supply chain solution. The alliance will be
designed to leverage EVERSANA's position as the leading provider of
commercial services addressing access, affordability and adherence
challenges for cell and gene therapies and Cryoport's complete
suite of temperature-controlled logistics solutions to ensure a
safe and effective supply chain solution for innovative therapeutic
This broad-based strategic alliance will be offered to current
and prospective clients to support the development of
groundbreaking regenerative medicines, including CAR T-cell and
"The promise of regenerative medicine requires an innovative
look at the complete product life cycle from market access planning
through efficient distribution and best-in-class patient support.
With Cryoport, we add real time logistics solutions with its
standard setting Chain of Compliance™, which includes "chain of
condition", "chain of custody" and "chain of identity", to our
global distribution and patient service capabilities," said
Jim Lang, EVERSANA CEO. "Their
temperature-controlled logistics solutions are currently used by
almost all of the leading biopharma companies. Our alliance will
drive synergistic revenue growth for both of our companies and
provide synergistic value to our clients."
Jerrell Shelton, Cryoport CEO
added, "Through our alliance, Cryoport will provide EVERSANA and
its clients with our full suite of logistics solutions under our
'powered by cryoport™' marketing model. This includes
our Cryoport Express® Shippers,
Cryoportal® Logistics Management Platform, leading-edge
SmartPak II™ Condition Monitoring System and our advanced logistics
management. EVERSANA is building a powerhouse, currently serving
over 500 life sciences companies, over 100 therapeutics areas,
including cell and gene therapies, across 80 countries. As we
continue to systematically develop our technologies and services,
our alliance will enable us to broaden the distribution of our
solutions and more broadly answer demand from regenerative medicine
companies for temperature-controlled for supply chain services. We
are proud to partner with EVERSANA to offer an advanced integrated
supply chain solution to our collective base of clients. The
regenerative therapy market is in its infancy with support
requirements evolving and this alliance is designed to capture the
vast opportunities at the "head of the stream.'"
About Cryoport, Inc.
Cryoport is the life sciences
industry's most trusted global provider of temperature-controlled
logistics solutions for temperature-sensitive life sciences
commodities, serving the biopharmaceutical market with leading-edge
logistics solutions for biologic materials, such as regenerative
medicine, including immunotherapies, stem cells and CAR-T cells.
Cryoport also provides a range of bioservices to the life sciences
industry, including biostorage for biological specimens, materials
and samples. Cryoport's solutions are used by points-of-care,
CRO's, central laboratories, pharmaceutical companies,
manufacturers, university researchers et al; as well as the
reproductive medicine market, primarily in IVF and surrogacy; and
the animal health market, primarily in the areas of vaccines and
reproduction. Cryoport's proprietary Cryoport
Express® Shippers, Cryoportal® Logistics Management Platform,
leading-edge SmartPak II™ Condition Monitoring System and
geo-sensing technology, paired with unparalleled cold chain
logistics expertise and 24/7 client support, make Cryoport the
end-to-end cold chain logistics partner that the industry trusts.
Cryoport is dedicated to: simplifying global cold chain logistics
through innovative technology, unmatched monitoring and data
capture and support, including consulting; delivering the most
advanced temperature-controlled logistics solutions for the life
sciences industry; and providing vital information that provides
peace of mind throughout the life of each logistics process.
For more information, visit www.cryoport.com. Sign up to
follow @cryoport on
Twitter at www.twitter.com/cryoport.
EVERSANA™ is the leading independent
provider of global services to the life science industry. The
company's integrated solutions are rooted in the patient experience
and span all stages of the product lifecycle to deliver long-term,
sustainable value for patients, prescribers, channel partners and
payers. The company serves more than 500 organizations, including
innovative start-ups and established pharmaceutical companies to
advance life science solutions for a healthier world. To learn more
about EVERSANA, visit EVERSANA.com or connect
through LinkedIn and Twitter.
Forward Looking Statements
this news release which are not purely historical, including
statements regarding Cryoport, Inc.'s intentions, hopes, beliefs,
expectations, representations, projections, plans or predictions of
the future are forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. It is important
to note that the Company's actual results could differ materially
from those in any such forward-looking statements. Factors that
could cause actual results to differ materially include, but are
not limited to, risks and uncertainties associated with the effect
of changing economic conditions, trends in the products markets,
variations in the Company's cash flow, market acceptance risks, and
technical development risks. The Company's business could be
affected by a number of other factors, including the risk factors
listed from time to time in the Company's SEC reports including,
but not limited to, the Company's 10-K for the year ended
December 31, 2018 filed with the SEC.
The Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release.
Cryoport, Inc. disclaims any obligation, and does not undertake to
update or revise any forward-looking statements in this press
View original content to download
SOURCE Cryoport, Inc.